Technical Analysis for CRBU - Caribou Biosciences, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 3.85 | -1.53% | -0.06 |
Earnings due: May 7
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | -1.53% | |
| Narrow Range Bar | Range Contraction | -1.53% | |
| Inside Day | Range Contraction | -1.53% | |
| Wide Bands | Range Expansion | -1.53% | |
| Oversold Stochastic | Weakness | -1.53% | |
| Wide Bands | Range Expansion | -1.53% | |
| Down 3 Days in a Row | Weakness | -1.53% |
| Alert | Time |
|---|---|
| Down 3% | about 12 hours ago |
| Down 2 % | about 12 hours ago |
| Outside Day | about 14 hours ago |
| Fell Below Previous Day's Low | about 14 hours ago |
| Down 1% | about 14 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/07/2024
Caribou Biosciences, Inc. Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Solid Tumors Cancer Immunotherapy Cell Therapy Cell Biology Leukemia Multiple Myeloma Breakthrough Therapy Hematologic Malignancies Chimeric Antigen Receptor T Cell T Cells CD19 Refractory Acute Myeloid Leukemia Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.5899 |
| 52 Week Low | 3.44 |
| Average Volume | 1,639,395 |
| 200-Day Moving Average | 5.68 |
| 50-Day Moving Average | 5.86 |
| 20-Day Moving Average | 4.54 |
| 10-Day Moving Average | 4.15 |
| Average True Range | 0.30 |
| RSI (14) | 22.48 |
| ADX | 33.3 |
| +DI | 10.30 |
| -DI | 31.84 |
| Chandelier Exit (Long, 3 ATRs) | 4.87 |
| Chandelier Exit (Short, 3 ATRs) | 4.68 |
| Upper Bollinger Bands | 5.47 |
| Lower Bollinger Band | 3.61 |
| Percent B (%b) | 0.13 |
| BandWidth | 41.07 |
| MACD Line | -0.53 |
| MACD Signal Line | -0.52 |
| MACD Histogram | -0.008 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.23 | ||||
| Resistance 3 (R3) | 4.24 | 4.14 | 4.16 | ||
| Resistance 2 (R2) | 4.14 | 4.04 | 4.13 | 4.14 | |
| Resistance 1 (R1) | 3.99 | 3.98 | 3.94 | 3.98 | 4.12 |
| Pivot Point | 3.89 | 3.89 | 3.86 | 3.88 | 3.89 |
| Support 1 (S1) | 3.74 | 3.79 | 3.69 | 3.73 | 3.58 |
| Support 2 (S2) | 3.64 | 3.73 | 3.63 | 3.56 | |
| Support 3 (S3) | 3.49 | 3.64 | 3.54 | ||
| Support 4 (S4) | 3.48 |
